Navigating Humana Enhertu Prior Authorization for Oncology Therapies

Understanding Enhertu Coverage with Humana

Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate indicated for specific HER2-positive cancers, including breast, gastric, and non-small cell lung cancers. As a high-cost specialty oncology medication, Enhertu typically requires prior authorization from Humana across commercial, Medicare Advantage, and Medicaid managed care plans. Coverage determinations are based on medical necessity criteria, often aligning with NCCN Clinical Practice Guidelines in Oncology, and for Medicare Advantage, must also adhere to applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs).

Humana Prior Authorization Submission Channels for Enhertu

Humana utilizes multiple channels for prior authorization submissions, depending on the benefit (medical or pharmacy) and the specific line of business. For Enhertu, which is typically administered intravenously, medical benefit prior authorizations are common, routing through established provider portals or electronic data interchange. Pharmacy benefit specialty drugs, if applicable, follow distinct pathways.

Key Submission Pathways for Enhertu PA with Humana

• **Medical Benefit (Medicare Advantage & Commercial):** Primary submission via Availity Essentials portal, which surfaces Humana's PA initiation tool and document upload capabilities.
• **Electronic Data Interchange (EDI):** X12 278 transactions are accepted via clearinghouses for medical benefit prior authorizations.
• **Specialty Pharmacy Benefit:** If Enhertu is covered under the pharmacy benefit (e.g., for self-administered forms not typical for Enhertu), CenterWell Specialty Pharmacy manages these workflows.
• **Retail Pharmacy ePA:** For pharmacy benefit drugs, prescriber-initiated electronic prior authorizations route through partners like CoverMyMeds or Surescripts ePA.

Policy Access and Medical Necessity Criteria

Humana publishes its medical policies and coverage determination documents on its provider site. For oncology medications like Enhertu, these policies frequently reference NCCN Compendium-based criteria. For Humana Medicare Advantage plans, it is critical to remember that prior authorization criteria cannot be more restrictive than Original Medicare’s coverage rules, ensuring alignment with relevant NCDs and LCDs. Klivira helps integrate these policy libraries directly into your PA workflow.

Turnaround Times and CMS-0057-F Compliance

Humana publishes precertification turnaround commitments on its provider site. For Medicare Advantage lines, which constitute a significant portion of Humana’s enrollment, statutory timeframes apply. With the implementation of CMS-0057-F, Humana, as an impacted payer, is subject to phased compliance requirements, including a standard prior authorization decision timeframe of 7 calendar days and an expedited timeframe of 72 hours for certain transactions, effective with the rule's phased rollout. Klivira's automation helps track these critical timelines.

Common Denial Reasons and Appeal Pathways for Enhertu

Denials for Enhertu prior authorizations from Humana may arise from reasons such as insufficient documentation of medical necessity (e.g., not meeting NCCN criteria), non-coverage under NCD/LCD for Medicare Advantage, or failure to meet step therapy requirements if applicable. Humana returns denial reasons via X12 277/835 and portal status updates. The appeal pathway is documented in Humana's provider manual, with Medicare Advantage appeals following the CMS-mandated 5-level structure. Peer-to-peer reviews are also available to address clinical rationales.